RIvaroxaban in mitral stenosis (RISE MS): A pilot randomized clinical trial.
Int J Cardiol
; 356: 83-86, 2022 06 01.
Article
de En
| MEDLINE
| ID: mdl-35306032
ABSTRACT
BACKGROUND:
Patients with moderate-to-severe mitral stenosis (MS) have bee excluded from all major randomized controlled trials (RCTs) comparing non-vitamin K antagonist oral anticoagulants (NOACs) with warfarin in patients with atrial fibrillation (AF). METHODS ANDRESULTS:
In this pilot RCT, 40 patients were randomized to rivaroxaban 20 mg daily or warfarin. No patients experienced symptomatic ischemic strokes and systemic embolic events (the primary composite study outcome) during a 12-month follow-up. No major bleeding was reported. During the follow-up, 18.2% of patients in both groups showed echocardiographic signs of increased thrombogenicity in the left atrial appendage. The rate of silent cerebral ischemia was 13.3% in the rivaroxaban group and 17.6% in the warfarin group at brain magnetic resonance imaging.CONCLUSION:
Our results suggest acceptable efficacy and safety for rivaroxaban in patients with AF and moderate-to-severe MS and are encouraging for larger RCTs in this so far neglected setting (NCT03926156).Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Fibrillation auriculaire
/
Accident vasculaire cérébral
/
Sténose mitrale
Type d'étude:
Clinical_trials
/
Etiology_studies
Limites:
Animals
/
Humans
Langue:
En
Journal:
Int J Cardiol
Année:
2022
Type de document:
Article
Pays d'affiliation:
Iran